Table 3.
Treatment, complications, and clinical outcomes of the patients.
| All Patients (n = 141) | Early Group (n = 84) | Late Group (n = 57) | P | |
|---|---|---|---|---|
| Immune plasma | 2 (1–3) | 2 (1–3) | 2 (2–3) | 0.737 |
| Immune plasma administration day | 5 (2−8) | 3 (2−4) | 8.5 (7−11) | 0.00* |
| Oxygen inhalation, n (%) | 67 (47.2 %) | 40 (47.6 %) | 27 (47.4 %) | 0.962 |
| Invasive mechanic ventilation, n (%) | 74 (52.1 %) | 44 (52.4 %) | 30 (52.7 %) | |
| Vasopressor, n (%) | 54 (38.0 %) | 31 (36.9 %) | 23 (40.4 %) | 0.680 |
| Renal replacement therapy, n (%) | 34 (23.9 %) | 14 (16.7 %) | 20 (35.1 %) | 0.012* |
| Tracheostomy, n (%) | 12 (8.4 %) | 7 (8.3 %) | 5 (8.8 %) | 0.927 |
| Median stay (days) in ICU (IQR) | ||||
| All patients | 10 (7–14) | 9 (6–14) | 11 (7.3– | 0.124 |
| Died | 11 (8–14) | 10 (7–14) | 14.8) | 0.264 |
| Discharged | 8.5 (6–14) | 8 (6–14) | 11 (9–13.5) | 0.363 |
| 10 (5–16) | ||||
| Discharged from ICU, n (%) | 69 (49.3 %) | 41 (48.8 %) | 28 (49.1 %) | 0.971 |
| Died, n (%) | 72 (50.7 %) | 43 (51.2 %) | 29 (50.9 %) |
*
p < 0.05.